Head-to-head · free
SOPHiA GENETICS S.A. vs TScan Therapeutics, Inc.
SOPH vs TCRX — return on capital, cash generation, margins and balance sheet side by side.
SOPH
2 / 3
measures where SOPH leads
TCRX
1 / 3
measures where TCRX leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | SOPH | TCRX · FY2025 |
|---|---|---|
| Revenue | — | $10.3M |
| Net income | — | (129.8M) |
| Revenue growth (yearly, multi-year) | — | 0.5% |
| Free cash flow | — | (139.7M) |
| Free cash flow margin | — | -1353.3% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -110.0% | -71.3% |
| Gross margin | 67.4% | — |
| Operating margin | -91.8% | -1315.4% |
| Net debt / EBITDA | 0.37x | 0.90x |
Figures are as reported by each company; latest fiscal year shown.
Where TScan Therapeutics, Inc.'s cash went (FY2025)
- Capital spending
- $4.4M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free